

Kelvin K Chan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3593228/kelvin-k-chan-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

187
papers

1,693
citations

23
h-index

34
g-index

202
ext. papers

2,313
ext. citations

3.8
avg. IF

5.08
L-index

#	Paper	IF	Citations
187	Parametric Survival Extrapolation of Early Survival Data in Economic Analyses: A Comparison of Projected Versus Observed Updated Survival.. <i>Value in Health</i> , 2022 , 25, 622-629	3.3	2
186	Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.. <i>JAMA Oncology</i> , 2022 ,	13.4	2
185	Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer.. <i>JAMA Network Open</i> , 2022 , 5, e2145460	10.4	2
184	Impact of cancer surgery slowdowns on patient survival during the COVID-19 pandemic: a microsimulation modelling study.. <i>Cmaj</i> , 2022 , 194, E408-E414	3.5	2
183	Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.. <i>Current Oncology</i> , 2022 , 29, 2046-2063	2.8	
182	Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 173, 103660	7	0
181	Placement technique impacts gastrostomy tube-related complications amongst head and neck cancer patients.. <i>Oral Oncology</i> , 2022 , 130, 105903	4.4	0
180	The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer. <i>JAMA Network Open</i> , 2021 , 4, e2133388	10.4	2
179	Impact of the COVID-19 Pandemic on Primary Care Access for Patients with Hematologic Malignancies. <i>Blood</i> , 2021 , 138, 4011-4011	2.2	1
178	Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.. <i>Current Oncology</i> , 2021 , 28, 4645-4654	2.8	2
177	Incidence of Mental Health Events and Its Association with Survival Among Patients with Diffuse Large B-Cell Lymphoma: A Population-Based Cohort Study. <i>Blood</i> , 2021 , 138, 1969-1969	2.2	
176	The Edmonton Symptom Assessment System: A narrative review of a standardized symptom assessment tool in head and neck oncology. <i>Oral Oncology</i> , 2021 , 123, 105595	4.4	0
175	Examining the association between oncology drug clinical benefit and the time to public reimbursement. <i>Cancer Medicine</i> , 2021 , 11, 380	4.8	1
174	A cost-utility analysis of apalutamide for metastatic castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2021 ,	1.2	1
173	Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group. <i>Current Oncology</i> , 2021 , 28, 4174-4183	2.8	3
172	The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. <i>Neuro-Oncology</i> , 2021 , 23, 894-904	1	16
171	Trajectory of End-of-Life Pain and Other Physical Symptoms among Cancer Patients Receiving Home Care. <i>Current Oncology</i> , 2021 , 28, 1641-1651	2.8	1

170	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. <i>European Journal of Health Economics</i> , 2021 , 22, 723-733	3.6	2
169	The impact of socioeconomic status on stage at presentation, receipt of diagnostic imaging, receipt of treatment and overall survival in colorectal cancer patients. <i>International Journal of Cancer</i> , 2021 , 149, 1031-1043	7.5	3
168	Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT). <i>Pharmacoeconomics</i> , 2021 , 39, 1075-1084	4.4	
167	Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time. <i>European Journal of Cancer</i> , 2021 , 150, 203-210	7.5	1
166	Patient-reported symptoms in metastatic gastric cancer patients in the last 6 months of life. <i>Supportive Care in Cancer</i> , 2021 , 29, 515-524	3.9	6
165	Trajectory of psychosocial symptoms among home care patients with cancer at end-of-life. <i>Psycho-Oncology</i> , 2021 , 30, 103-110	3.9	5
164	Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada. <i>International Journal of Cancer</i> , 2021 , 148, 1910-1918	7.5	2
163	Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. <i>MDM Policy and Practice</i> , 2021 , 6, 23814683211021060	1.5	2
162	Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs. <i>Current Oncology</i> , 2021 , 28, 606-618	2.8	1
161	Salvage surgery for locally recurrent anal cancer after intensity modulated radiation therapy with concurrent chemotherapy. <i>Cancer Treatment and Research Communications</i> , 2021 , 26, 100287	2	0
160	Understanding the Feasibility of Implementing CAR T-Cell Therapies from a Canadian Perspective. <i>Healthcare Policy</i> , 2021 , 16, 89-105	1.1	
159	Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review. <i>JAMA Network Open</i> , 2021 , 4, e2033004	10.4	9
158	Patient-Reported Symptom Burden as a Predictor of Emergency Department Use and Unplanned Hospitalization in Head and Neck Cancer: A Longitudinal Population-Based Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 675-684	2.2	10
157	End-of-life outcomes with or without early palliative care: a propensity score matched, population-based cancer cohort study. <i>BMJ Open</i> , 2021 , 11, e041432	3	2
156	Reply to K. Yokoyama et al. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2417-2419	2.2	1
155	Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy. <i>BMJ Open</i> , 2021 , 11, e046707	3	0
154	Effect of Early Palliative Care on End-of-Life Health Care Costs: A Population-Based, Propensity Score-Matched Cohort Study. <i>JCO Oncology Practice</i> , 2021 , OP2100299	2.3	3
153	The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group. <i>Current Oncology</i> , 2021 , 28, 3649-3658	2.8	

152	Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study.. <i>BMC Medical Research Methodology</i> , 2021 , 21, 282	4.7	
151	Evaluation of the impact of patient involvement in health technology assessments: A scoping review. <i>International Journal of Technology Assessment in Health Care</i> , 2020 , 36, 217-223	1.8	1
150	The Theoretical Relationship between Sample Size and Expected Predictive Precision for EQ-5D Valuation Studies: A Mathematical Exploration and Simulation Study. <i>Medical Decision Making</i> , 2020 , 40, 339-347	2.5	4
149	Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. <i>BMJ Open</i> , 2020 , 10, e032884	3	18
148	Systemic therapy in metastatic renal cell carcinoma: Emerging challenges in therapeutic choice. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 102971	7	4
147	Socioeconomic disparity trends in diagnostic imaging, treatments, and survival for non-small cell lung cancer 2007-2016. <i>Cancer Medicine</i> , 2020 , 9, 3407-3416	4.8	9
146	A Cost-Utility Analysis of Magnetic Resonance (MR) Guided Brachytherapy Versus Two-Dimensional and Computed Tomography (CT) Guided Brachytherapy for Locally Advanced Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 107, 512-521	4	4
145	Nonsurgical management of resectable oral cavity cancer in the wake of COVID-19: A rapid review and meta-analysis. <i>Oral Oncology</i> , 2020 , 109, 104849	4.4	7
144	The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 1132-1137	3.6	2
143	Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations. <i>Human Reproduction</i> , 2020 , 35, 434-445	5.7	4
142	Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study. <i>Lancet Haematology</i> , 2020 , 7, e146-e156	14.6	12
141	Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 155-165	4.4	8
140	Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer. <i>JCO Oncology Practice</i> , 2020 , 16, e201-e210	2.3	7
139	Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 278-285	7.3	5
138	Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives. <i>CMAJ Open</i> , 2020 , 8, E772-E778	2.5	3
137	High-Cost Patients and Preventable Spending: A Population-Based Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 23-31	7.3	2
136	Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis. <i>Cancer Medicine</i> , 2020 , 9, 160-169	4.8	34
135	Health technology assessment methodology in metastatic renal cell carcinoma. <i>Nature Reviews Urology</i> , 2020 , 17, 3-5	5.5	2

134	Value-based pricing: Toward achieving a balance between individual and population gains in health benefits. <i>Cancer Medicine</i> , 2020 , 9, 94-103	4.8	2
133	Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 145, 102817	7	14
132	Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics. <i>Cancer</i> , 2020 , 126, 1717-1726	6.4	12
131	Metastasis to gastrostomy sites from upper aerodigestive tract malignancies: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2020 , 91, 1005-1014.e17	5.2	10
130	Value assessment of oncology drugs using a weighted criterion-based approach. <i>Cancer</i> , 2020 , 126, 15306-15407	6.1	7
129	Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer?. <i>Cancer Medicine</i> , 2020 , 9, 215-224	4.8	8
128	Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups. <i>Value in Health</i> , 2020 , 23, 1157-1162	3.3	2
127	Impact of rarity on Canadian oncology health technology assessment and funding. <i>International Journal of Technology Assessment in Health Care</i> , 2020 , 1-6	1.8	1
126	Predictors of surgical readmission, unplanned hospitalization and emergency department use in head and neck oncology: A systematic review. <i>Oral Oncology</i> , 2020 , 111, 105039	4.4	4
125	The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma. <i>Cancer Medicine</i> , 2020 , 9, 7072-7082	4.8	3
124	Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. <i>Breast Cancer Research and Treatment</i> , 2020 , 179, 217-227	4.4	7
123	Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada. <i>BMC Cancer</i> , 2020 , 20, 304	4.8	7
122	Estimating hazard ratios from published Kaplan-Meier survival curves: A methods validation study. <i>Research Synthesis Methods</i> , 2019 , 10, 465-475	7.2	25
121	Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs. <i>Heart</i> , 2019 , 105, 1649-1655	5.1	3
120	Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials. <i>JAMA Oncology</i> , 2019 , 5, 1188-1194	13.4	9
119	Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB). <i>Medical Decision Making</i> , 2019 , 39, 370-378	2.5	9
118	Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations. <i>Cancer Medicine</i> , 2019 , 8, 1584-1593	4.8	11
117	Health Utility Book (HUB)-Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer. <i>MDM Policy and Practice</i> , 2019 , 4, 2381468319852594	1.5	

116	The impact of pricing strategy on the costs of oral anti-cancer drugs. <i>Cancer Medicine</i> , 2019 , 8, 3770-3781.	1.8	5
115	Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale. <i>JAMA Network Open</i> , 2019 , 2, e196803	10.4	9
114	Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Clinical Benefit-In Reply. <i>JAMA Oncology</i> , 2019 , 5, 1807-1808	13.4	
113	Pembrolizumab alone or with chemotherapy for PD-L1 positive NSCLC: A network meta-analysis of randomized trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9087-9087	2.2	3
112	A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 247-247	2.2	1
111	A phase I study of MR-HIFU hyperthermia (HT) with radiation (RT) and chemotherapy (CT) for recurrent rectal cancer. 2019 , 5, 78-78		2
110	Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1489-1496	7.3	3
109	A network meta-analysis of adjuvant systemic therapy in resected pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 396-396	2.2	
108	Measuring the long-term fail of curve survival benefits in oncology trials: A comparison of the ASCO Value Framework and the ESMO Magnitude of Clinical Benefit Scale.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2585-2585	2.2	
107	Do the ASCO Value Framework and the ESMO Magnitude of Clinical Benefit Scale measure Absolute or Relative clinical benefit?. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18378-e18378	2.2	
106	Comparison of outcomes in a population-based cohort of women with metastatic breast cancer receiving anti-HER2 therapy with clinical trial outcomes.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1037-1037 ²	2.2	
105	A weighted criterion-based approach to value assessment of oncology drugs.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6627-6627	2.2	
104	Drug funding price negotiations: Towards achieving a balance between individual and population gains in health benefits.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6641-6641	2.2	
103	Impact of health behavior change on health utility (HU) and financial toxicity in head and neck cancer (HNC) survivors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11561-11561	2.2	
102	A cost-utility analysis of atezolizumab in the second-line treatment of metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6639-6639	2.2	
101	Magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) hyperthermia for primary rectal cancer: A virtual feasibility analysis. 2019 , 5, 77-77		
100	Demographic characteristics and cost of treatment among oncology patients in a publicly funded system, the Ontario Trillium Drug Program: a retrospective cohort study. <i>CMAJ Open</i> , 2019 , 7, E516-E523 ⁵	3.5	1
99	Peri-Infarct Quantification by Cardiac Magnetic Resonance to Predict Outcomes in Ischemic Cardiomyopathy: Prognostic Systematic Review and Meta-Analysis. <i>Circulation: Cardiovascular Imaging</i> , 2019 , 12, e009156	3.9	10

98	Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1399-1408	1.9	3
97	Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort. <i>Head and Neck</i> , 2018 , 40, 2029-2042	4.2	14
96	Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis. <i>International Journal of Cancer</i> , 2018 , 143, 430-437	7.5	38
95	The economic burden of cancer care in Canada: a population-based cost study. <i>CMAJ Open</i> , 2018 , 6, E1-E10	10	55
94	Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer. <i>European Urology</i> , 2018 , 74, 57-62	10.2	33
93	Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy. <i>International Journal of Cardiology</i> , 2018 , 261, 228-233	3.2	40
92	Conducting EQ-5D Valuation Studies in Resource-Constrained Countries: The Potential Use of Shrinkage Estimators to Reduce Sample Size. <i>Medical Decision Making</i> , 2018 , 38, 26-33	2.5	2
91	Immunotherapy (IO) versus non-IO for oncology drugs: Comparing survival benefits (SB) using restricted mean survival time.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6617-6617	2.2	1
90	Comparative effectiveness and safety of the implementation of universal public funding of FOLFIRINOX (FFX) and gemcitabine (G) + nab-paclitaxel (GnP) in advanced pancreatic cancer (APC): A population-based study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 375-375	2.2	2
89	Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate (AA) and enzalutamide (E) in advanced prostate cancer: clinical value and cost considerations.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 276-276	2.2	1
88	Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 472-472	2.2	
87	Chemotherapy choice in advanced pancreatic cancer: What patient and disease factors influence prescription patterns?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 327-327	2.2	
86	Implementation of an electronic referral smoking cessation tool into clinical practice across cancer clinics of different disease sites and institutions.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 112-112	2.2	
85	Use of QT interval prolonging drugs (QT drugs) and electrocardiogram (ECG) monitoring in patients (pts) receiving first-line anti-cancer systemic therapy (tx): A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6598-6598	2.2	
84	Gastrointestinal (GI) cancer (CA) drugs approved by the US Food and Drug Administration (FDA): Clinical value and cost considerations.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6619-6619	2.2	
83	Assessing the difference in efficacy and effectiveness of cancer systemic treatment (tx): A comparison of clinical trial (CT) overall survival (OS) and toxicity data with population-based, real world (RW) OS data.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6581-6581	2.2	
82	A descriptive analysis of clinician input and feedback into the CADTH pan-Canadian Oncology Drug Review process.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 42-42	2.2	
81	Are real-world patient-reported outcomes associated with survival in patients with advanced pancreatic cancer?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 205-205	2.2	

80	Examining Convergent Construct Validity and Inter-Rater Reliability Between ESMO-MCBS and ASCO-VF When Evaluating Hematologic Malignancies. <i>Blood</i> , 2018 , 132, 4800-4800	2.2	
79	Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013. <i>Cancer</i> , 2018 , 124, 1269-1278	6.4	10
78	A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 113-120	3.8	46
77	Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research Groups. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky050	4.6	4
76	Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time. <i>Journal of Oncology Practice</i> , 2018 , 14, e280-e294	3.1	44
75	Quality of life changes after stereotactic ablative radiotherapy for liver metastases: A prospective cohort analysis. <i>Radiotherapy and Oncology</i> , 2018 , 129, 435-440	5.3	6
74	Estimates and predictors of health care costs of esophageal adenocarcinoma: a population-based cohort study. <i>BMC Cancer</i> , 2018 , 18, 694	4.8	7
73	Economic evaluation of smoking cessation in Ontario's regional cancer programs. <i>Cancer Medicine</i> , 2018 , 7, 4765-4772	4.8	8
72	Do older and younger patients derive similar survival benefits from novel oncology drugs? A systematic review and meta-analysis. <i>Age and Ageing</i> , 2018 , 47, 654-660	3	2
71	Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database. <i>Cancer Medicine</i> , 2018 , 7, 2816	4.8	11
70	Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018 , 144, 71-79	3.9	22
69	Underestimation of Variance of Predicted Health Utilities Derived from Multiattribute Utility Instruments. <i>Medical Decision Making</i> , 2017 , 37, 262-272	2.5	9
68	Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. <i>Value in Health</i> , 2017 , 20, 586-592	3.3	11
67	Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials. <i>Clinical Lung Cancer</i> , 2017 , 18, 345-353.e5	4.9	14
66	Cetuximab plus irinotecan versus panitumumab in patients with refractory metastatic colorectal cancer in Ontario, Canada. <i>International Journal of Cancer</i> , 2017 , 140, 2162-2167	7.5	4
65	Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2017 , 19, 44	6.9	31
64	Engaging specialist oncologists in the assessment of oncology drugs in Canada. <i>Lancet Oncology, The</i> , 2017 , 18, 573-575	21.7	
63	A network meta-analysis of the sequencing and types of systemic therapies with definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN)?. <i>Oral Oncology</i> , 2017 , 71, 1-10	4.4	7

62	Financial Impact of Cancer Drug Wastage and Potential Cost Savings From Mitigation Strategies. <i>Journal of Oncology Practice</i> , 2017 , 13, e646-e652	3.1	11
61	Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2764-2771	2.2	44
60	Impact of a New Palliative Care Program on Health System Finances: An Analysis of the Palliative Care Program Inpatient Unit and Consultations at Johns Hopkins Medical Institutions. <i>Journal of Oncology Practice</i> , 2017 , 13, e421-e430	3.1	22
59	The impact of cancer drug wastage on economic evaluations. <i>Cancer</i> , 2017 , 123, 3583-3590	6.4	6
58	Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting. <i>Cancer Medicine</i> , 2017 , 6, 2017-2033	4.8	12
57	Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. <i>Oncologist</i> , 2017 , 22, 694-699	5.7	19
56	A Bayesian network meta-analysis on second-line systemic therapy in advanced gastric cancer. <i>Gastric Cancer</i> , 2017 , 20, 646-654	7.6	11
55	Do elderly and young patients derive similar relative survival benefits from novel oncology drugs? A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10029-10029	2.2	1
54	Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting. <i>PLoS ONE</i> , 2017 , 12, e0185198	3.7	15
53	Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. <i>Healthcare Policy</i> , 2017 , 12, 95-108	1.1	17
52	The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	48
51	Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. <i>Journal of Oncology Practice</i> , 2016 , 12, e710-23	3.1	17
50	Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?. <i>ESMO Open</i> , 2016 , 1, e000124	6	4
49	Phase-specific and lifetime costs of cancer care in Ontario, Canada. <i>BMC Cancer</i> , 2016 , 16, 809	4.8	45
48	Salivary duct carcinoma: Treatment, outcomes, and patterns of failure. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E820-6	4.2	63
47	Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach. <i>Medical Decision Making</i> , 2016 , 36, 223-33	2.5	9
46	Is there any benefit to adding adjuvant chemotherapy after concurrent chemoradiotherapy for nasopharyngeal carcinoma?. <i>European Journal of Cancer</i> , 2016 , 56, 186-187	7.5	1
45	ABVD Versus Combination Baseline Beacopp/Escalated Beacopp in the Treatment of Newly Diagnosed Advanced-Stage Hodgkin Lymphoma: A Decision Analysis. <i>Blood</i> , 2016 , 128, 1183-1183	2.2	1

44	Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1428-9	2.2	9
43	Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. <i>CMAJ Open</i> , 2016 , 4, E66-72	2.5	9
42	Associations among socioeconomic status, patterns of care and outcomes in breast cancer patients in a universal health care system: Ontario's experience. <i>Cancer</i> , 2016 , 122, 893-8	6.4	32
41	Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review. <i>Journal of Oncology Practice</i> , 2016 , 12, e369-79	3.1	27
40	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016 , 67, 174-182	7.5	46
39	Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 535-44	4.4	12
38	Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 1570-9	7.5	50
37	The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015 , 15, 81-100	2.2	3
36	Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer. <i>Radiation Oncology</i> , 2015 , 10, 95	4.2	4
35	Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D. <i>Breast Cancer Research and Treatment</i> , 2015 , 150, 169-80	4.4	9
34	Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 137-145	4.4	5
33	Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy. <i>The Cochrane Library</i> , 2015 , CD010341	5.2	17
32	Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer. <i>Breast Journal</i> , 2015 , 21, 658-64	1.2	10
31	Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis. <i>Cancer</i> , 2015 , 121, 2637-45	6.4	16
30	ASCO Provisional Clinical Opinion for Hepatitis B Virus Screening Before Cancer Therapy: Are These the Right Tests in the Right Patients?. <i>Journal of Oncology Practice</i> , 2015 , 11, e490-4	3.1	2
29	A Systematic Review and Network Meta-Analysis of Biologic Agents in the First Line Setting for Advanced Colorectal Cancer. <i>PLoS ONE</i> , 2015 , 10, e0140187	3.7	5
28	A systematic review of post first-line treatments for advanced gastrointestinal stromal tumor (GIST): Direct pairwise meta-analyses and indirect comparisons.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 195-195	2.2	
27	A network meta-analysis-based cost-effectiveness analysis of systematic therapies in advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6611-6611	2.2	1

26	Cardiac care after myocardial infarction in cancer survivors: A population-based study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9578-9578	2.2	
25	Interpreting the febrile neutropenia rates from randomized controlled trials for consideration of primary prophylaxis in the real world: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9626-9626	2.2	
24	A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer. <i>PLoS ONE</i> , 2014 , 9, e108749	3.7	27
23	Underestimation of uncertainties in health utilities derived from mapping algorithms involving health-related quality-of-life measures: statistical explanations and potential remedies. <i>Medical Decision Making</i> , 2014 , 34, 863-72	2.5	23
22	Chemotherapy-induced cardiotoxicity: detection, prevention, and management. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 869-78	3.8	75
21	Burnout among Canadian oncologists and oncology residents.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6549-6549	2.2	1
20	Long-term risk of heart failure associated with adjuvant trastuzumab in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9504-9504	2.2	2
19	Pharmacokinetic (PK) assessment of dacomitinib (D) in patients with locoregionally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through gastrostomy feeding tube (GT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e17049-e17049	2.2	
18	Associations among socioeconomic status (SES), patterns of care and outcomes in breast cancer (BC) patients (pts) in a universal health care system: Ontario's experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6625-6625	2.2	
17	Adjuvant taxane therapy for early-stage breast cancer: A real-world comparison of chemotherapy regimens in Ontario.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1081-1081	2.2	
16	A Bayesian multiple-treatments meta-analysis of neoadjuvant treatments for locally advanced, resectable esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4074-4074	2.2	
15	Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6024-6024	2.2	
14	An electronic prompt prior to myelosuppressive therapy to improve hepatitis B virus screening.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6627-6627	2.2	
13	HBV screening before adjuvant chemotherapy in patients with early breast cancer: A cost-effectiveness analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11-11	2.2	
12	An electronic prompt to improve hepatitis B virus screening prior to cancer treatment.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 169-169	2.2	
11	Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. <i>CMAJ Open</i> , 2013 , 1, E1-8	2.5	71
10	Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study. <i>CMAJ Open</i> , 2013 , 1, E151-8	2.5	35
9	Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6041-6041	2.2	5

- 8 Less than ideal: how oncologists practice with limited drug access. *Journal of Oncology Practice*, **2012**, 8, 190-5 3.1 8
- 7 Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. *Journal of Clinical Oncology*, **2012**, 30, 1064-71 2.2 25
- 6 Serious adverse events among a population-based cohort of patients receiving first-line chemotherapy for metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2012**, 30, e14003-e14003³ 2.2 3
- 5 Oncology education in Canadian undergraduate and postgraduate medical programs: A survey of educators and learners.. *Journal of Clinical Oncology*, **2012**, 30, e16558-e16558 2.2 1
- 4 A multicenter analysis of prognostic factors in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib.. *Journal of Clinical Oncology*, **2012**, 30, e14532-e14532 2.2
- 3 G-CSF as Secondary Prophylaxis of Febrile Neutropenia In the Management of Advanced-Stage Hodgkin Lymphoma Treated with ABVD Chemotherapy: A Decision Analysis.. *Blood*, **2010**, 116, 3831-3831² 2
- 2 A Systematic Approach for the Simultaneous Assay of Some Antituberculous Drugs in CSF and Plasma by Liquid Chromatography. *Journal of Liquid Chromatography and Related Technologies*, **1988**, 11, 1051-1073 7
- 1 Pharmacokinetic contributions to drug use. *Journal of Clinical Pharmacy and Therapeutics*, **1985**, 10, 257-67